Publication date: Aug 08, 2024
A trial performed among unvaccinated, high-risk outpatients with COVID-19 during the delta period showed remdesivir reduced hospitalization. We used our real-world data platform to determine the effectiveness of remdesivir on reducing 28-day hospitalization among outpatients with mild-moderate COVID-19 during an Omicron period including BQ. 1/BQ. 1.1/XBB. 1.5. We did a propensity-matched, retrospective cohort study of non-hospitalized adults with SARS-CoV-2 infection between April 7, 2022, and February 7, 2023. Electronic healthcare record data from a large health system in Colorado were linked to statewide vaccination and mortality data. We included patients with a positive SARS-CoV-2 test or outpatient remdesivir administration. Exclusion criteria were other SARS-CoV-2 treatments or positive SARS-CoV-2 test more than seven days before remdesivir. The primary outcome was all-cause hospitalization up to day 28. Secondary outcomes included 28-day COVID-related hospitalization and 28-day all-cause mortality. Among 29,270 patients with SARS-CoV-2 infection, 1,252 remdesivir-treated patients were matched to 2,499 untreated patients. Remdesivir was associated with lower 28-day all-cause hospitalization (1. 3% vs. 3. 3%, adjusted hazard ratio (aHR) 0. 39 [95% CI 0. 23-0. 67], p
Open Access PDF
Concepts | Keywords |
---|---|
Colorado | COVID-19 |
February | Nonhospitalized |
Outpatient | Omicron variant |
Outpatient | |
Remdesivir | |
SARS-CoV-2 | |
Veklury |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
disease | VO | unvaccinated |
disease | VO | effectiveness |
pathway | REACTOME | SARS-CoV-2 Infection |
disease | VO | vaccination |
disease | MESH | Infectious Diseases |
disease | IDO | symptom |
disease | MESH | death |
drug | DRUGBANK | Ritonavir |
disease | VO | population |
disease | VO | immunization |
disease | MESH | emergency |
disease | VO | ineffective |
disease | MESH | comorbidity |
drug | DRUGBANK | Trestolone |
drug | DRUGBANK | Pentaerythritol tetranitrate |
disease | MESH | treatment failure |
disease | MESH | obesity |
disease | MESH | hypertension |
disease | MESH | cardiovascular disease |
disease | MESH | diabetes mellitus |
disease | MESH | pulmonary disease |
drug | DRUGBANK | Oxygen |
drug | DRUGBANK | Isoxaflutole |
disease | VO | dose |
disease | VO | time |
disease | IDO | process |
disease | VO | age |
disease | MESH | Liver Disease |
disease | VO | vaccinated |
disease | IDO | healthcare facility |
disease | MESH | drug interactions |
disease | VO | publication |
disease | VO | USA |
disease | VO | injection |
drug | DRUGBANK | Coenzyme M |
disease | VO | report |
disease | VO | VacA |
disease | MESH | contraindications |